WASHINGTON (dpa-AFX) - Biopharmaceutical company Seelos Therapeutics Inc. (SEEL) announced Thursday that it has received a positive opinion on European Orphan Drug Designation for SLS-005 in Amyotrophic
Share this article
Share this article
NEW YORK, May 27, 2021 /PRNewswire/ Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has received European Orphan Drug Designation for SLS-005 in amyotrophic lateral sclerosis (ALS) from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP).
Under orphan designation in the European Union (EU), Seelos stands to benefit from several incentives such as protocol assistance, reduced regulatory fees and market exclusivity. European guidelines for Orphan Drug Designation are for diseases affecting not more than five in 10,000 people in the EU.
Operator
Good day, and thank you for standing by. Welcome to the Sangamo First Quarter 2021 Teleconference Call. [Operator Instructions].
I would now like to hand the conference over to your speaker today, Aron Feingold, Head of Corporate Communications. Please go ahead.
Aron Feingold
Head of Corporate Communications
Good afternoon, and thank you for joining us today. With me this afternoon on this call are several members of the Sangamo executive leadership team, including Sandy Macrae, Chief Executive Officer; Mark McClung, Chief Business Officer; Jason Fontenot, Chief Scientific Officer; Rob Schott, Head of Development; and Bettina Cockroft, Chief Medical Officer. Slides from our corporate presentation can be found on our website, sangamo.com, under the Investors and Media section on the Events and Presentations page.